Clinical Trials on Polyarthritis, Juvenile, Rheumatoid Factor Negative in Japan

Total 12 results

Abbott
Eisai Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis

Japan
Pfizer

Completed

Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance] (Enbrel-JIA)

Juvenile Idiopathic Arthritis

Japan
Swedish Orphan Biovitrum
CMIC Co, Ltd. Japan

Recruiting

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Still's Disease, Adult-Onset | Still's Disease, Juvenile Onset

Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Systemic Juvenile Idiopathic Arthritis

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

Juvenile Idiopathic Arthritis

Japan
AbbVie

Recruiting

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. (SELECT-sJIA)

Juvenile Idiopathic Arthritis

United States, Japan, Turkey, Australia, China, Spain, Italy, Germany, Brazil, United Kingdom
AbbVie

Active, not recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis (SELECT-YOUTH)

Juvenile Idiopathic Arthritis (JIA)

United States, Canada, Germany, Hungary, Israel, Italy, Japan, Puerto Rico, Spain, Sweden
Eli Lilly and Company

Recruiting

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Systemic Juvenile Idiopathic Arthritis

Belgium, Spain, India, Italy, Czechia, Japan, Austria, France, United Kingdom, Brazil, Mexico, Israel, Poland, Argentina, Denmark, Turkey
Eli Lilly and Company

Recruiting

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)

Juvenile Idiopathic Arthritis

Belgium, Spain, Australia, India, Japan, Italy, Czechia, Austria, France, United Kingdom, Mexico, Israel, Brazil, China, Denmark, Germany, Poland, Russian Federation, Argentina, Turkey
Eli Lilly and Company

Completed

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-BASIS)

Juvenile Idiopathic Arthritis

Spain, India, Israel, Japan, Australia, Belgium, Turkey, Mexico, Italy, Germany, Czechia, United Kingdom, China, Russian Federation, Poland, Brazil, France, Austria, Argentina, Denmark
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Hepatocellular Carcinoma | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancers | Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Head and Neck Squamous-Cell Carcinoma

United States, Israel, Japan, Puerto Rico, Korea, Republic of, Taiwan
University of Oxford
American College of Rheumatology; The European League Against Rheumatism (EULAR) and other collaborators

Unknown

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS)

Giant Cell Arteritis | Wegener's Granulomatosis | Microscopic Polyangiitis | Polyarteritis Nodosa | Takayasu Arteritis | Churg Strauss Syndrome

Korea, Republic of, United States, Germany, Australia, Japan, Ireland, Belgium, Italy, Denmark, Slovenia, Switzerland, Canada, Argentina, Austria, China, Czech Republic, Egypt, Finland, France, Hungary, India, Mexico, Netherlands, New... and more

Clinical Trials on Polyarthritis, Juvenile, Rheumatoid Factor Negative in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations